DNMT1 and cancer: Likewise, many epigenetic drugs, such as bromodomain inhibitors, HDAC inhibitors, and DNMT inhibitors, sensitize cancer cells to PARPi, likely converting HR-proficient cancer cells to HR-deficient cells, termed ‘induced BRCAness’ [86,87,88,89,90].